Harry Dent has the chutzpah to pretend to know what the stock market is going to do for the next ten years. His performance track record says otherwise. Read More
Jim Fink is chief investment strategist for Options for Income, Velocity Trader, and Jim Fink's Inner Circle. He has traded options for more than 30 years and generated personal profits of more than $5 million. Jim also serves as an investment analyst at Investing Daily’s flagship investing publication, Personal Finance.
Hopelessly overeducated, Jim holds a bachelor's degree from Yale University, a master's degree from Harvard's Kennedy School of Government, a law degree from Columbia University, and an MBA from the University of Virginia's Darden School of Business. For good measure, he has been a member of the Illinois and D.C. bars.
Prior to joining Investing Daily, and when not incurring student loans hiding out in academe, Jim practiced telecommunications regulatory law for nine years until he realized that he made more money trading stock options than writing briefs. After attending business school, Jim switched gears to the investment realm full-time, working for a university endowment, a private wealth management firm, an insurance and financial planning company, and as a Senior Analyst for an online investment newsletter service that encourages the wearing of funny hats.
A possible but unlikely descendant of legendary brawler and boatman Mike Fink, Jim defies his heritage, believing that investing success requires patience and analysis, not swashbuckling bravado. Besides his passion for analyzing and writing about stocks, Jim likes to hike in the desert Southwest, vacation in Las Vegas, play tennis, and feed his toddler son Cheerios.
Analyst Articles
This telecom giant’s long-awaited addition of the iPhone to its product lineup during 2011 spurred growth in the number of its customers who use smartphones. Read More
In our inaugural issue, we wring rare income from a non-dividend paying biopharmaceutical outfit whose blockbuster treatment for multiple myeloma is one of the top-selling oncology drugs in the world. Read More
The best performing stocks all started out as small-capitalization stocks. Small-cap stocks in general have outperformed the market over time. Read More
As Jim predicted, Procter & Gamble has decided to walk away from its deal to sell Pringles potato chips to Diamond Foods because of Diamond's accounting irregularities. Read More
Facebook will go public during the first half of this year and its stock will probably skyrocket on its first day. Jim believes it will perform better than most Internet IPOs, but it's no Google. Read More
A balancing act between slowing economic growth and anticipated additional monetary easing has global stock markets rising steadily (for now). Read More
Investors are fleeing mutual funds for more personalized financial advice. Jim explains why trust is more important than an advisor's past track record of investment performance. Read More
When attempting to value banks, different rules apply. Why debt and cash are trickier concepts in the bank context. Read More
2012 is shaping up to be an "annus horribilis" for the drug industry thanks to a large number of patent expirations. Some drug stocks will thrive regardless and Jim names a few. Read More